By Traci Hacker

Corium, Inc. announced the U.S. Food and Drug Administration (FDA) has approved Corium’s ADLARITY (donepezil transdermal system) as a treatment for those with mild, moderate, or severe dementia of the Alzheimer’s type. ADLARITY is the first and only once-weekly patch to continuously deliver consistent doses of donepezil through the skin. This delivery mechanism results in a low likelihood of adverse gastrointestinal side effects associated with oral donepezil. Corium plans to launch sales of the new medication in early fall 2022. Corium, Inc. is a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system therapies. Corium’s proprietary…